基本信息
views: 137
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
His research focuses on epigenetics, ALK, tumor microenvironment, STAS and artificial intelligence (AI) in lung cancer. He discovered several novel resistance mechanisms against ALK inhibitors when he worked at National Kyushu Cancer Center. Thereafter, he intensively investigated the significance of PD-L1 and STAS in resected lung cancer at Kyushu University. Dr. Toyokawa has authored or co-authored around 140 papers on lung cancer and other thoracic malignancies. He actively collaborates with medical oncologists, radiologists, pathologists and basic scientists to better manage the lung cancer patients.
Research Interests
Papers共 236 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yuko Nagata,Gouji Toyokawa,Akiko Sugiyama,Shinichiro Shimamatsu, Ohki Saitoh, Hiroshi Okubo,Hitoshi Ueda
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitionersno. 4 (2024): 772-776
CELL REPORTSno. 8 (2023)
crossref(2023)
crossref(2023)
crossref(2023)
Cell reportsno. 8 (2023): 112899-112899
Cancer medicineno. 13 (2023): 14327-14336
Critical reviews in oncology/hematology (2023): 103966-103966
crossref(2023)
Load More
Author Statistics
#Papers: 241
#Citation: 5545
H-Index: 43
G-Index: 66
Sociability: 6
Diversity: 3
Activity: 36
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn